MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone loss

Abstract Objective Diabetic osteoporosis is a secondary complication of diabetes mellitus, characterized by reduced bone mass, increased bone fragility, and impaired fracture healing. However, the mechanisms underlying diabetic bone loss remain to be fully elucidated. More importantly, there is an u...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chaofeng Wang, Na Hai, Liuyuan Chen, Qian Huang, Ying Gui, Yuangang Su, Haoyu Lian, Jiamin Liang, Jinmin Zhao, Jiake Xu, Qian Liu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2026-01-01
Edice:	Journal of Translational Medicine
Témata:	Osteoclast MPC OXPHOS ROS Bone loss
On-line přístup:	https://doi.org/10.1186/s12967-026-07699-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!